G protein-coupled receptor 68Genealiases: AI2A6 · GPR12A · OGR1
Q-omics provides the consensus-scored GPR68 profile across patient tissues and cancer cell-line models. GPR68 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GPR68 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, GPR68 RNA expression shows 20,231 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where GPR68 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR68 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR68 survival associations across molecular data types. GPR68 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR68 RNA expression–survival associations across cancer types. High GPR68 expression shows unfavorable associations in UVM, KIRC, KIRP, BLCA and ACC, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GPR68 RNA expression.
This table summarizes GPR68 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GPR68. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR68 shows higher tumor expression in HNSC, COAD, BRCA, STAD, CHOL and LIHC. The HNSC box plot shows higher GPR68 RNA expression in tumor versus normal tissue (log2 FC = +1.376, t-test p < 0.001).
This table shows molecular features associated with GPR68 in patient tissues and cancer cell lines. In patient samples, GPR68 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR68 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
